NDSI
UTHR icon

Newman Dignan & Sheerar Inc’s United Therapeutics UTHR Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,969
Closed -$343K – 149
2015
Q2 		$343K Buy
+1,969
New +$354K 0.25% 103

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 30.2% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Newman Dignan & Sheerar Inc's UTHR Position: Q3 2015 in Review

Newman Dignan & Sheerar Inc sold out of United Therapeutics (UTHR) in Q3 2015, closing a stake of 1,969 shares — an estimated $343K sold.

Newman Dignan & Sheerar Inc first reported a position in UTHR in Q2 2015 and held it in 1 quarter. The position peaked at $343K in Q2 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2015.

  • Newman Dignan & Sheerar Inc reported no remaining United Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Newman Dignan & Sheerar Inc sold 1,969 United Therapeutics shares in Q3 2015, an estimated $343K.
  • Newman Dignan & Sheerar Inc first reported a position in United Therapeutics in Q2 2015 and held it in 1 quarter.
  • Newman Dignan & Sheerar Inc's United Therapeutics position peaked at $343K in Q2 2015.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2015.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2015, filed 23 Oct 2015.